Literature DB >> 9724849

Partial lipodystrophy, mesangiocapillary glomerulonephritis, and complement dysregulation. An autoimmune phenomenon.

Y Levy1, J George, E Yona, Y Shoenfeld.   

Abstract

Partial lypodistrophy (PLD) is a rare disease in which, there is loss of fat usually from the upper part of the body. The disease is frequently associated with mesangiocapillary (membranoproliferative) glomerulonephritis Type II (MCGN II). In the early 1970s, it was noticed that MCGN II and/or PLD was sometimes associated with dysfunction of the complement system as reported in several case descriptions and studies. Subsequently, an IgG autoantibody was detected-C3 nephritic factor (C3NeF). The target of this autoantibody is the alternative pathway C3 convertase-C3bBb. There are sporadic case reports that linked PLD, MCGNII, and C3NeF with autoimmune diseases. This association may be more than a coincidence. The complement deficiency may lead to perturbation of the immune system, which may trigger some of the autoimmune diseases. This article will be focused on the association among PLD, MCGN II and C3NeF.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9724849     DOI: 10.1007/BF02786513

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  41 in total

1.  Dense deposit disease: a variant of membranoproliferative glomerulonephritis.

Authors:  R Habib; M C Gubler; C Loirat; H B Mäiz; M Levy
Journal:  Kidney Int       Date:  1975-04       Impact factor: 10.612

2.  Is membranoproliferative glomerulonephritis an autoimmune disease?

Authors:  H Ohi; Y Tanuma; M Hatano
Journal:  Nephron       Date:  1990       Impact factor: 2.847

3.  Renal disease in partial lipodystrophy.

Authors:  A J Eisinger; J R Shortland; P J Moorhead
Journal:  Q J Med       Date:  1972-07

4.  Human anti-idiotypic antibody responses to autoantibody against the alternative pathway C3 convertase.

Authors:  R E Spitzer; A E Stitzel; G C Tsokos
Journal:  Clin Immunol Immunopathol       Date:  1990-10

5.  Lupus, C3 nephritic factor and partial lipodystrophy.

Authors:  C C Cronin; T J Higgins; M Molloy
Journal:  QJM       Date:  1995-04

6.  Molecular analysis of C3 allotypes in patients with nephritic factor.

Authors:  J E Finn; P W Mathieson
Journal:  Clin Exp Immunol       Date:  1993-03       Impact factor: 4.330

7.  Multiple autoimmune diseases with bilateral optic atrophy and lipodystrophy.

Authors:  W A Wilson; J G Sissons; O S Morgan
Journal:  Ann Intern Med       Date:  1978-07       Impact factor: 25.391

8.  Partial lipodystrophy, C3 nephritic factor and clinically inapparent mesangiocapillary glomerulonephritis.

Authors:  W M Bennett; E J Bardana; K Wuepper; D Houghton; W A Border; O Götze; R Schreiber
Journal:  Am J Med       Date:  1977-05       Impact factor: 4.965

9.  C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase.

Authors:  M R Daha; D T Fearon; K F Austen
Journal:  J Immunol       Date:  1976-01       Impact factor: 5.422

Review 10.  C3 nephritic factor and SLE: report of four cases and review of the literature.

Authors:  M J Walport; K A Davies; M Botto; M A Naughton; D A Isenberg; D Biasi; R J Powell; N T Cheung; G R Struthers
Journal:  QJM       Date:  1994-10
View more
  8 in total

1.  Partial lipodystrophy, polycystic ovary syndrome and proteinuria: a common link to insulin resistance?

Authors:  V C Blackwell; P Salis; R W Groves; S E Baldeweg; G S Conway; R J Unwin
Journal:  J R Soc Med       Date:  2001-05       Impact factor: 5.344

Review 2.  Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed?

Authors:  G M Behrens; M Stoll; R E Schmidt
Journal:  Drug Saf       Date:  2000-07       Impact factor: 5.606

Review 3.  Autoimmunity in Primary Immunodeficiencies (PID).

Authors:  Grace T Padron; Vivian P Hernandez-Trujillo
Journal:  Clin Rev Allergy Immunol       Date:  2022-06-01       Impact factor: 8.667

4.  A CASE OF ACQUIRED GENERALIZED LIPODYSTROPHY ASSOCIATED WITH PEMBROLIZUMAB IN A PATIENT WITH METASTATIC MALIGNANT MELANOMA.

Authors:  Sara Bedrose; Christie G Turin; Victor R Lavis; Sang T Kim; Sonali N Thosani
Journal:  AACE Clin Case Rep       Date:  2020-01-03

5.  Complement factor I deficiency: a not so rare immune defect: characterization of new mutations and the first large gene deletion.

Authors:  María Alba-Domínguez; Alberto López-Lera; Sofía Garrido; Pilar Nozal; Ignacio González-Granado; Josefa Melero; Pere Soler-Palacín; Carmen Cámara; Margarita López-Trascasa
Journal:  Orphanet J Rare Dis       Date:  2012-06-18       Impact factor: 4.123

Review 6.  Complement system in dermatological diseases - fire under the skin.

Authors:  Jaana Panelius; Seppo Meri
Journal:  Front Med (Lausanne)       Date:  2015-01-29

Review 7.  Nephritic Factors: An Overview of Classification, Diagnostic Tools and Clinical Associations.

Authors:  Fernando Corvillo; Marcin Okrój; Pilar Nozal; Marta Melgosa; Pilar Sánchez-Corral; Margarita López-Trascasa
Journal:  Front Immunol       Date:  2019-04-24       Impact factor: 7.561

8.  Complement factor H is expressed in adipose tissue in association with insulin resistance.

Authors:  José María Moreno-Navarrete; Rubén Martínez-Barricarte; Victoria Catalán; Mònica Sabater; Javier Gómez-Ambrosi; Francisco José Ortega; Wifredo Ricart; Mathias Blüher; Gema Frühbeck; Santiago Rodríguez de Cordoba; José Manuel Fernández-Real
Journal:  Diabetes       Date:  2009-10-15       Impact factor: 9.461

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.